FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.269,66 -376,20 (-0,63%)
GlucoTrack, Inc. (GCTK)
Dopo ore:
| Chiusura precedente | 0,4600 |
| Aperto | 0,4789 |
| Denaro | 0,4560 x 100 |
| Lettera | 0,4729 x 100 |
| Min-Max giorno | 0,4521 - 0,4800 |
| Intervallo di 52 settimane | 0,1330 - 0,9900 |
| Volume | |
| Media Volume | 180.834 |
| Capitalizzazione | 12,182M |
| Beta (5 anni mensile) | 0,29 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3800 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study
- GlobeNewswire
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS
Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held va
- GlobeNewswire
GLUCOTRACK ANNOUNCES NEW VP OF MARKETING
Rutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing. Ms. Benjamin has over 20 years of experience in life sciences, with specific focus on commercialization of health technology. Within diabetes, she has past experiences in product deve
